A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors

被引：0
作者：
Gerald S Falchook
Jasgit Sachdev
Esteban Rodrigo Imedio
Sanjeev Kumar
Ganesh M Mugundu
Suzanne Jenkins
Juliann Chmielecki
Suzanne Jones
David R Spigel
Melissa Johnson
机构：
[1] Sarah Cannon Research Institute at HealthONE,Oncology R&D
[2] HonorHealth Research Institute,Clinical Pharmacology and Quantitative Pharmacology, CPSS
[3] AstraZeneca,Translational Medicine, Early Research and Development
[4] AstraZeneca,undefined
[5] AstraZeneca,undefined
[6] Sarah Cannon Research Institute,undefined
[7] Tennessee Oncology,undefined
来源：
Investigational New Drugs | 2023年 / 41卷
关键词：
Adavosertib; AZD1775; Cancer; Wee1; Clinical trial; Phase I;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Adavosertib selectively inhibits Wee1, which regulates intra-S and G2/M cell-cycle checkpoints. This study investigated dosing schedules for adavosertib monotherapy, determining the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) in patients with advanced solid tumors.
引用
收藏
页码：493 / 502
页数：9
相关论文
共 69 条
[1]  
Watanabe N(1995)Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle EMBO J 14 1878-1891
[2]  
Broome M(2011)Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease J Cell Biol 194 567-579
[3]  
Hunter T(2009)Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents Mol Cancer Ther 8 2992-3000
[4]  
Dominguez-Kelly R(2012)Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption Mol Cell Biol 32 4226-4236
[5]  
Martin Y(2010)MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil Cancer Biol Ther 9 514-522
[6]  
Koundrioukoff S(2011)MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts Clin Cancer Res 17 2799-2806
[7]  
Hirai H(2013)Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy Mol Cancer Ther 12 1442-1452
[8]  
Iwasawa Y(2012)MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells Mol Cancer Ther 11 174-182
[9]  
Okada M(2015)Phase I study of single-agent AZD1775 (MK-1775), a WEE1 kinase inhibitor, in patients with refractory solid tumors J Clin Oncol 33 3409-3415
[10]  
Beck H(2021)Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma J Clin Oncol 39 1531-1539
1234567